---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000043"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:05:01.192225+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arvinas licenses ARV-766 to Novartis for $150M upfront; up to $1.01B in milestones

## Summary
- Arvinas grants Novartis exclusive worldwide license to develop and commercialize ARV-766 for prostate cancer.
- Novartis pays $150M upfront; Arvinas eligible for up to $1.01B in development, regulatory, and commercial milestones plus tiered royalties.
- Asset purchase includes Arvinas' preclinical AR-V7 program sold to Novartis.
- Novartis assumes full responsibility for global clinical development and commercialization of ARV-766.
- Closing subject to HSR antitrust waiting period expiration or termination.

## SEC filing metadata
- accession: 0001655759-24-000043
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000043/0001655759-24-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000043/arvn-20240410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000043
- JSON: https://secwatch.observer/filing/0001655759-24-000043.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000043.txt

## Key facts
- Material Agreements
  ARVINAS, INC. entered into License Agreement with Novartis Pharma AG valued at $150.0 million upfront, up to $1.01 billion in milestones (effective 2024-04-10).
  - Action: entry
  - Agreement: license
  - Counterparty: Novartis Pharma AG
  - Value: $150.0 million upfront, up to $1.01 billion in milestones
  - Effective: 2024-04-10
  source text: On April 10, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), entered into a transaction (the “Transaction”), including both a license agreement (the “License Agreement”) and an asset purchase agreement (the “Asset Agreement”), with Novartis Pharma AG (“Novartis”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000043/0001655759-24-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.